Arch Biopartners Obtains DTC Eligibility for its Common Shares on OTCQB
21 août 2020 08h00 HE
|
Arch Biopartners
TORONTO, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced it has obtained eligibility with The Depository Trust...
Arch Biopartners to Hold LSALT Peptide Webinar Today at 11am EST
18 août 2020 08h16 HE
|
Arch Biopartners
TORONTO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) will host a webinar today at 11:00am EST to present an overview of the...
Broward Health Medical Center Becomes First Clinical Site in U.S. for Phase II Trial for LSALT Peptide
28 juil. 2020 08h13 HE
|
Arch Biopartners
TORONTO, July 28, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
Arch Biopartners Arranges Non-Brokered Private Placement
24 juin 2020 08h41 HE
|
Arch Biopartners
TORONTO, June 24, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
Arch Biopartners Submits Investigational New Drug Application to the FDA for Metablok (LSALT peptide)
08 juin 2020 07h00 HE
|
Arch Biopartners
TORONTO, June 08, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
Arch Biopartners Expands the Primary Endpoint of its Phase II Trial to Include Prevention of Multiple Organ Injuries in Patients with COVID-19
19 mai 2020 16h31 HE
|
Arch Biopartners
TORONTO, May 19, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating...
Arch Biopartners Receives Health Canada Approval to Conduct COVID-19 Phase II Human Trial
08 mai 2020 06h00 HE
|
Arch Biopartners
TORONTO, May 08, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating...
Arch Biopartners Submits Application to Health Canada to Conduct COVID19 Phase II Human Trial for Metablok to Prevent Lung and Kidney Inflammation
23 avr. 2020 16h54 HE
|
Arch Biopartners
TORONTO, April 23, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating...
Arch Biopartners Expands Dosing in Phase I Trial for Metablok to Increase Dose Range for Future Phase II Studies
04 mars 2020 09h56 HE
|
Arch Biopartners
TORONTO, March 04, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it is expanding the dose range of Metablok...
Arch Biopartners Announces Metablok Achieves Primary Endpoints of Safety and Tolerability in Phase I Trial
18 déc. 2019 09h27 HE
|
Arch Biopartners
TORONTO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Phase I human trial of Metablok (LSALT...